Skip directly to content

Welcome

  • Information on ELIQUIS

    ELIQUIS® is approved in Australia for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors and for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults.

  • Education & media

    Education slides, videos and information resources

     
  • ELIQUIS Support Materials

    Information and resources to assist you and your patients at every touch point of the patient's journey

Real-world research presented

  • Clinical trial information
    Randomised clinical trials and real-world research come together to help inform treatment decisions. What does this mean? Real-world data complement randomised clinical trial results to provide additional information to assist...

References

References

  1. Granger CB, Alexander JH, McMurray JJ. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011;365:981-992.